Highlight
– At 12 months post-VA-ECMO, approximately 30% of patients are alive without new disability.
– Most new disability events occur within the first 6 months following VA-ECMO initiation.
– By 12 months, significantly more patients regain independence in activities of daily living and fewer remain unemployed due to health reasons.
– Outcomes vary considerably based on the underlying reason for VA-ECMO therapy initiation.
Study Background and Disease Burden
Venoarterial extracorporeal membrane oxygenation (VA-ECMO) is a lifesaving intervention used in critically ill adult patients experiencing severe cardiac or cardiopulmonary failure. Traditionally, research on VA-ECMO has focused on short-term survival and hemodynamic stabilization, whereas long-term functional outcomes and quality of life have remained inadequately characterized. Given the invasive nature and complexity of VA-ECMO, survivors may endure significant morbidity, including new disabilities that affect everyday functioning and employment. Addressing this gap, the EXCEL study, a prospective, multicenter effort, sought to quantify death or new disability incidence at 6 and 12 months after VA-ECMO initiation, furnishing critical patient-centered outcomes to better inform clinical decision-making and post-ECMO rehabilitation strategies.
Study Design
This prospective cohort study was embedded within a large registry and conducted across 26 hospitals in Australia and New Zealand from February 2019 to April 2023. Adult patients admitted to participating intensive care units (ICUs) undergoing VA-ECMO were consecutively enrolled. The primary outcome was the composite incidence of death or newly acquired disability assessed at both 6 and 12 months post-VA-ECMO initiation. Disability was operationalized based on loss of independence in activities of daily living and impediments affecting employment status. Analysis adjusted for baseline patient characteristics at ECMO initiation to control for confounding factors. Secondary analyses stratified outcomes by the clinical indication for VA-ECMO use.
Key Findings
Among 389 adult patients treated with VA-ECMO (median age 57 years, 35% female), the composite endpoint of death or new disability was 70.8% at 6 months and 70.6% at 12 months, indicating no statistically significant change between these intervals (adjusted odds ratio [aOR] for 12 vs. 6 months: 0.61; 95% confidence interval [CI] 0.25-1.49; P=0.27). Notably, functional improvements were observed between 6 and 12 months:
– Independence in activities of daily living increased significantly from 48.2% at 6 months to 62.1% at 12 months (aOR 2.84, 95% CI 1.50-5.36; P=0.001).
– Unemployment due to health reasons decreased from 47.4% at 6 months to 32.7% at 12 months (aOR 0.29, 95% CI 0.13-0.65; P<0.001).
These findings collectively indicate a plateau in mortality and new disability incidence by 6 months but continued functional recovery thereafter. Furthermore, the study demonstrated heterogeneity in long-term outcomes tied to the underlying etiology of cardiac failure prompting VA-ECMO, underscoring the importance of individualized prognostic counseling.
Expert Commentary
The EXCEL study presents landmark data on long-term patient-centered outcomes after VA-ECMO, shifting focus from survival alone toward meaningful functional recovery. The high burden of death or new disability highlights the severe post-critical illness morbidity associated with VA-ECMO, consistent with findings from previous single-center or retrospective analyses. Importantly, the improvement in independence and employment status between 6 and 12 months supports ongoing rehabilitation and follow-up interventions during this critical recovery window.
Potential limitations include the observational design and potential residual confounding despite adjustment, as well as the absence of detailed neurocognitive or psychological assessments which may further delineate disability. Additionally, outcome variability by ECMO indication suggests that future research should stratify interventions and prognostic models accordingly. These data complement evolving ECMO guidelines, which increasingly advocate for multidisciplinary post-ECMO rehabilitation programs to optimize recovery.
Conclusion
One year after VA-ECMO initiation, nearly one-third of adult patients survive free from new disability, while the majority experience death or persistent morbidity. The primary accumulation of disability occurs within the first 6 months, followed by stabilization and some functional improvements up to 12 months. Long-term morbidity varies by the clinical context of VA-ECMO use, emphasizing personalized prognostic evaluation. These findings advocate for integrated long-term care pathways focusing on functional recovery, including early rehabilitation and employment support, to enhance survivor outcomes after VA-ECMO.
References
Serpa Neto A, Higgins AM, Bailey MJ, et al; EXCEL Study Investigators on behalf of the International ECMO Network (ECMONet). Long-Term Functional Outcomes in the First 12 Months After VA-ECMO in Adult Patients: A Prospective, Multicenter Study. Circ Heart Fail. 2025 Jun;18(6):e012476. doi: 10.1161/CIRCHEARTFAILURE.124.012476. Epub 2025 Apr 29. PMID: 40298907.
ClinicalTrials.gov. NCT03793257. https://www.clinicaltrials.gov/ct2/show/NCT03793257